Ovarian cancer drug safety check: what side effects did 354 patients report?
NCT ID NCT05021562
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at side effects of the drug niraparib (Zedula) in 354 people with ovarian cancer. Participants took niraparib capsules once a day as part of their normal care, and doctors recorded any side effects for one year. The main focus was on serious side effects like low blood cell counts, high blood pressure, and lung problems. This was an observational study, meaning the drug was not being tested for how well it works, only for safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan